

# Module 12: Synthetic gene circuits and noise


CSE590: Molecular programming and neural computation.

# Biological inspiration

## DNA Genome

...GTGGTACAGGTG  
AATTTGGGTAGGCTA  
AATTGTCCATAGTTT  
ATGTGTGTGAATGAG  
GGTGTATGGATGTTT  
CTCAGAGATGGGTG  
CAGCTGGAAGGGCGT  
CCATTGGTCAAGTCA  
TATGCTGGAGAAGTT  
GCCGGTTCATTCTGC  
TGTGGCGACCCAGAA  
TTAATAAAAGGACTA  
AGCCGAAAAGAAAAT  
GAAACATATATATAT  
ATATATATATATATA  
TATATATATA...

## Regulatory Circuitry




## Zebrafish Development



Can we learn how to write such a program?

# State




# A bistable switch

## Construction of a genetic toggle switch in *Escherichia coli*


Timothy S. Gardner<sup>\*†</sup>, Charles R. Cantor<sup>\*</sup> & James J. Collins<sup>\*†</sup>

<sup>\*</sup> Department of Biomedical Engineering, <sup>†</sup> Center for BioDynamics and <sup>‡</sup> Center for Advanced Biotechnology, Boston University, 44 Cummington Street, Boston, Massachusetts 02215, USA



$$\frac{du}{dt} = \frac{\alpha_1}{1 + v^\beta} - U$$

$$\frac{dv}{dt} = \frac{\alpha_2}{1 + u^\gamma} - V$$





# A bistable switch

## Construction of a genetic toggle switch in *Escherichia coli*

Timothy S. Gardner<sup>\*†</sup>, Charles R. Cantor<sup>\*†</sup> & James J. Collins<sup>\*†</sup>

<sup>\*</sup> Department of Biomedical Engineering, <sup>†</sup> Center for BioDynamics and <sup>‡</sup> Center for Advanced Biotechnology, Boston University, 44 Cummington Street, Boston, Massachusetts 02215, USA






Problems:

Growth rate hit

Leak

Balance

# Rythm




# The repressilator

## A synthetic oscillatory network of transcriptional regulators




Michael B. Elowitz & Stanislas Leibler

Departments of Molecular Biology and Physics, Princeton University, Princeton, New Jersey 08544, USA



$$\frac{dm_i}{dt} = -m_i + \frac{\alpha}{(1 + p_j^n)} + \alpha_0 \quad \left( \begin{array}{l} i = lacI, tetR, cl \\ j = cl, lacI, tetR \end{array} \right)$$

$$\frac{dp_i}{dt} = -\beta(p_i - m_i)$$



# The Repressilator




A biological oscillator  
(Elowitz, 2001)


# An mammalian synthetic oscillator

## A tunable synthetic mammalian oscillator

Marcel Tigges<sup>1</sup>, Tatiana T. Marquez-Lago<sup>1,2,3</sup>, Jörg Stelling<sup>1,2,3</sup> & Martin Fussenegger<sup>1</sup>



# The complexity brake?



Priscilla E. M. Purnick & Ron Weiss  
Nature Reviews Molecular Cell Biology, 2009

# FIVE HARD TRUTHS FOR SYNTHETIC BIOLOGY

Can engineering approaches tame the complexity of living systems? **Roberta Kwok** explores five challenges for the field and how they might be resolved.

**1 Many of the parts are undefined**  
A biological part can be anything from a DNA sequence that encodes a specific protein to a promoter, a sequence that facilitates the expression of a gene. The problem is

**2 The circuitry is unpredictable**  
Even if the function of each part is known, the parts may not work as expected when put together, says Keasling.

**3 The complexity is unwieldy**  
As circuits get larger, the process of constructing and testing them becomes more daunting. A system developed by Keas-

**4 Many parts are incompatible**  
Once constructed and placed into cells, synthetic genetic circuits can have unintended effects on their host. Chris


**5 Variability crashes the system**  
Synthetic biologists must also ensure that circuits function reliably. Molecular activities inside cells are prone to random fluctuations, or noise. Variation in growth con-

**"The field has had its hype phase. Now it needs to deliver."  
— Martin Fussenegger**


# Why is it difficult to engineer synthetic gene circuits?

1. Synthetic gene circuits have to operate in a complex biological environment
2. Biology is “noisy” (small copy numbers of many molecules,...)
3. Existing parts aren't modular or well characterized


# A simple biological network




# A complex synthetic network




# A complex synthetic network



# An complex synthetic network



# Noise in gene expression





# Noise in gene expression

Consider genes for two fluorescent proteins controlled by identical promoters in *E. coli*



Monitor time-varying fluorescence within a single cell and across cell populations:  
cells with the same amount of each fluorescent protein species appear yellow,  
cells with differing amounts of the two species appear red or green

Without intrinsic noise, red and green signals are correlated within a single cell



Fluorescence **intensities** vary between cells due to extrinsic noise


With intrinsic noise, the red and green signals become uncorrelated within a single cell



Fluorescence **color** varies between cells due to intrinsic noise


# Noise in gene expression

Express reporter genes under lac-repressible promoters in *E. coli* strain (M22) lacking repressor protein lac



Minimal intrinsic noise without lac repression of reporter genes

Express reporter genes under lac-repressible promoters in wild-type *E. coli* strain (RP22) expressing repressor protein lac




Increased intrinsic and extrinsic noise due to lac repression

Extrinsic noise increase suggests cell-cell variation in lac expression

# Noise in gene expression

Quantification of intrinsic and extrinsic noise for populations of two strains of *E. coli*




Each point represents mean red and green fluorescence in a single cell

Strain M22 is less noisy  
Strain D22 is more noisy

# What can we do to make better gene circuits?



1. Create new parts and characterize them better
2. Design network architectures that are more robust to perturbations
3. ...

# An improved and tunable bistable switch



*lacZ13(Oc), lacI22, rpsL135 (strR), malT1*  
( $\lambda^R$ ), *xyl-7, mtl-1, thi-1*


$\Delta(araD-araB)567, \Delta lacZ4787(::rrnB-3), \lambda-, rph-1,$   
 $\Delta(rhaD-rhaB)568, hsdR514, \Delta lacI$



Egbert and Klavins, **Fine Tuning with Simple Sequence Repeats**, *Proceedings of the National Academy of Science*, Aug. 2012.

# An improved and tunable bistable switch

▶ Tuning via Changing the DNA:



This is what a gene for GFP production looks like.  
You can tune via

- Modifying the promoter so that RNAP sticks more or less efficiently.
- Changing the concentration of active transcription factor (e.g. LacI) → later.
- Changing the RBS (eg. longer spacers)
- Tweaking the RNA or Protein degradation rate by adding "degradation tags"


# An improved and tunable bistable switch

## Rewritable digital data storage in live cells via engineered control of recombination directionality

Jerome Bonnet, Pakpoom Subsoontorn, and Drew Endy<sup>1</sup>

Department of Bioengineering, Room 269B, Y2E2 Building, 473 Via Ortega, Stanford University, Stanford, CA 94305

Edited by David Baker, University of Washington, Seattle, WA, and approved April 6, 2012 (received for review February 8, 2012)







# An improved synthetic oscillator



LETTERS

## A fast, robust and tunable synthetic gene oscillator

Jesse Stricker<sup>1\*</sup>, Scott Cookson<sup>1\*</sup>, Matthew R. Bennett<sup>1,2\*</sup>, William H. Mather<sup>1</sup>, Lev S. Tsimring<sup>2</sup> & Jeff Hasty<sup>1,2</sup>




# An improved synthetic oscillator



A biological oscillator  
(Hasty lab)


# Cellular reprogramming




# Production of the antimalarial drug precursor artemisinic acid in engineered yeast

Dae-Kyun Ro<sup>1\*</sup>, Eric M. Paradise<sup>2\*</sup>, Mario Ouellet<sup>1</sup>, Karl J. Fisher<sup>6</sup>, Karyn L. Newman<sup>1</sup>, John M. Ndungu<sup>3</sup>, Kimberly A. Ho<sup>1</sup>, Rachel A. Eachus<sup>1</sup>, Timothy S. Ham<sup>4</sup>, James Kirby<sup>2</sup>, Michelle C. Y. Chang<sup>1</sup>, Sydnor T. Withers<sup>2</sup>, Yoichiro Shiba<sup>2</sup>, Richmond Sarpong<sup>3</sup> & Jay D. Keasling<sup>1,2,4,5</sup>

Malaria is a global health problem that threatens 300–500 million people and kills more than one million people annually<sup>1</sup>. Disease control is hampered by the occurrence of multi-drug-resistant strains of the malaria parasite *Plasmodium falciparum*<sup>2,3</sup>. Synthetic antimalarial drugs and malarial vaccines are currently being developed, but their efficacy against malaria awaits rigorous clinical testing<sup>4,5</sup>. Artemisinin, a sesquiterpene lactone endoperoxide extracted from *Artemisia annua* L (family Asteraceae; commonly known as sweet wormwood), is highly effective against multi-drug-resistant *Plasmodium* spp., but is in short supply and unaffordable to most malaria sufferers<sup>6</sup>. Although total synthesis of artemisinin is difficult and costly<sup>7</sup>, the semi-synthesis of artemisinin or any derivative from microbially sourced artemisinic acid, its immediate precursor, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin<sup>8,9</sup>. Here we report the engineering of *Saccharomyces cerevisiae* to produce high titres (up to 100 mg l<sup>-1</sup>) of artemisinic acid using an engineered mevalonate pathway, amorpha-4,11-diene synthase (ADS), and a novel cytochrome P450 monooxygenase (CYP71AV1) from *A. annua* that performs a three-step oxidation of amorpha-4,11-diene to artemisinic acid. The synthesized arte-



**Figure 2 | Production of amorpha-4,11-diene by *S. cerevisiae* strains.** The various *S. cerevisiae* strains are described in the text. Cultures were sampled after 144 h of growth, and amorpha-4,11-diene levels were quantified. Data, shown as total production, are mean ± s.d. ( $n = 3$ ).



Not much about metabolic engineering in this course.

# Applications

- Tissue Engineering
- Diagnostics
- Therapeutics
- Chemical Synthesis
- Materials

# SYNDUSTRY

The news of "Synthia," the world's first human-made species, is just the latest from a rapidly growing artificial life industry. Synthetic biology (or "Syn Bio") aims to profit from the design and construction of industrially useful life-forms.

## THE EMERGING SYNTHETIC BIOLOGY INDUSTRY



### Syn Bio's Big Shots

Global corporations are investing in synthetic biology labs and partnering with start-up companies.

*"Over the next 20 years synthetic genomics is going to become the standard for making anything."* - Craig Venter



**Cargill**  
Agribusiness giant. Supports synthetic biology R&D.

**BP**  
Energy giant. \$500 million partnership on synthetic biology with University of California Berkeley; holds equity stake in Craig Venter's Synthetic Genomics, Inc.


**Du Pont**  
Chemical giant. Developed first commercial syn bio product with Genencor and sugar giant Tate & Lyle - a fibre called Sorona.

**Pfizer**  
Pharma giant. Conducts in-house syn bio research for drug development.

**Virgin Group**  
Includes Virgin Fuels, investor in synthetic biology. Controlled by celebrity billionaire Richard Branson.

### Synthetic Startups

A bevy of 'pure play' syn bio companies is attempting to design synthetic microbes for fuel, chemicals and drugs. Many are university spin-offs.



**gevo**  
(USA) Developing synthetic biofuels with support from Virgin.

**Mascoma**  
(USA) Developing synthetic biofuels.

**Synthetic Genomics**  
(USA) Constructing synthetic life forms for biofuels and carbon sequestration.

**LS9**  
(USA) Developing synthetic biofuels and industrial chemicals.

**AMYRIS BIOTECHNOLOGIES**  
**Amyris Biotech**  
(USA) Developing cellular factories to produce drugs, fuels and industrial chemicals.

**ProtoLife**  
(Italy) Developing synthetic living systems.

### DNA Synthesis Foundries

DNA foundries produce the raw material for creating artificial life: synthetic DNA (sDNA). Over 70 DNA foundries

worldwide manufacture sDNA for genetic engineers and synthetic biologists. The market for sDNA already exceeds a billion dollars annually. Even long DNA sequences - entire genes, for example - can be ordered over the Internet and delivered within two weeks. The speed of producing accurate DNA sequences is doubling every two years and costs are halving even faster.

